Scott Salys Joins Presidio Medical as Chief R&D, Operations Officer

Presidio Medical Inc. has named Scott Salys as chief Research & Development and Operations officer.

Salys is a 25-year veteran in Class III active implantable devices leading R&D, operations, supply chain, program management, and durable medical equipment (DME) organizations. He joins the company from Abbott, where he was most recently divisional vice president of R&D within the Heart Failure business.
 
“We are thrilled to have someone with Scott’s breadth of experience across operations, supply chain, and R&D join the Presidio team. Not only does Scott have functional expertise in key areas for Presidio’s progression, but he has managed several business lines within cardiac rhythm management and neuromodulation, which is complimentary to the platform Presidio is building,” Presidio Medical Chairman/CEO Michael Onuscheck said.
 
Salys was the divisional Vice President of R&D (2021-2022) and divisional vice president of Operations (2017-2021) in Abbott’s Heart Failure business, where he led the organization through a phase of rapid growth and expansion. In addition to roles in R&D and Operations, Salys transformed the Heart Failure DME business by shifting strategy, building the team, and establishing a commercial organization that delivered triple digit growth. Salys also served on Abbott’s Executive Crisis Management Team, Scientific Governing Board, and the Board of Directors for Abbott Global Enterprises.
 
Before Abbott acquired St. Jude Medical (SJM) in 2017, Salys spent more than 16 years at SJM in R&D, operations, and supply chain roles across various divisions and geographies. His most recent roles at SJM included vice president of Operations and R&D, vice president of Supply Chain, vice president of Operations, and vice president of Program Management. Salys successfully integrated newly acquired businesses, strengthened global organizations, executed change management initiatives, and delivered rapid growth in the neuromodulation and cardiac resynchronization therapy markets.

“I am excited to join this team and lead Presidio Medical through the next stage of clinical and product development. We have the opportunity to create neuromodulation therapies for new patient populations as well as transform conventional neuromodulation therapy. I am passionate about building high-performing teams and look forward to delivering our novel ULF platform to patients,” Salys said.
 
Presidio Medical was founded in 2017 and is headquartered in South San Francisco. The clinical-stage, privately held medical device company is developing a neuromodulation platform to treat diseases of undesired neural activity with a first indication in the treatment of chronic pain. Presidio’s current investors include Invus Opportunities and Action Potential Venture Capital.